References
- World Health Organization (WHO): World Health Organization, Epilepsy, October 2016. [cited 2018 May 16]. Available from: http://www.who.int/mediacentre/factsheets/fs999/en/index.html
- Padaczka JJ. Wydawnictwo Czelej Sp. Lublin: z o.o; 2006.
- Jędrzejczak J. Padaczka - współczesne zasady diagnostyki i leczenia. Przewodnik Lekarza. 2002;5(9):26–32.
- Terczyński A. Co powinniśmy wiedzieć o padaczce. Ogólnopolski Przegląd Medyczny. 2008;7:41–44.
- Zieliński J. Padaczka. Przesądy i rzeczywistość. Warszawa: PZWL; 1979.
- Potrykowska A, Orzełek E Biuletyn 53, Rządowa rada ludnościowa, Warszawa, 2008. [cited 2018 May 16]. Available from: http://www.stat.gov.pl/cps/rde/xbcr/bip/BIP_rrl_biuletyn53.pdf.
- Duncan JS, Sander JW, Sisodiya SM, et al. Adult epilepsy. Lancet. 2006 Apr 1;367(9516):1087–1100.
- Moshé SL, Perucca E, Ryvlin P, et al. Epilepsy: new advances. Lancet. 2015 Mar 7;385(9971):884–898.
- Tyszko B, Staniszewska A. The effects of brand-generic substitution in antiepileptic treatment. Zdrowie Publiczne i Zarządzanie. 2016;14(4):254–258.
- EY. Metodyka pomiaru kosztów pośrednich w polskim systemie ochrony zdrowia. Warszawa, 2013. [cited 2018 May 16]. Available from: http://www.ey.com/Publication/vwLUAssets/Raport_Metodyka_pomiaru_kosztow_posrednich_17.09/$FILE/Raport_Metodyka%20pomiaru%20kosztow%20posrednich_17.09.pdf
- Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22(3):165–184.
- Fountain NB. Epilepsy. Dis Mon. 2003 Jul;49(7):426–478.
- Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet. 2000 Jul 22;356(9226):323–329.
- Olesen J, Gustavsson A, Svensson M, et al. CDBE2010 study group; European Brain Council. The economic cost of brain disorders in Europe. Eur J Neurol. 2012 Jan;19(1):155–162.
- Yoon D, Frick KD, Carr DA, et al. Economic impact of epilepsy in the United States. Epilepsia. 2009 Oct;50(10):2186–2191.
- Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia. 2002;43(Suppl 4):3–9.
- Baulac M, de Boer H, Elger C, et al. Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy advocacy europe task force. Epilepsia. 2015 Nov;56(11):1687–1695.
- Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia. 2007 Dec;48(12):2224–2233.
- Beran RG, Pachlatko C. Final report of the ILAE commission on economic aspects of epilepsy, 1994-1997. International league against epilepsy. Epilepsia. 1997 Dec;38(12):1359–1362.
- Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia. 1998 Jul;39(7):776–786.
- Forsgren I, Beghi E, Ekman M. Cost of epilepsy in Europe. Eur J Neurol. 2005 Jun;12(Suppl 1):54–58.
- Strzelczyk A, Reese JP, Dodel R, et al. Cost of epilepsy: a systematic review. Pharmacoeconomics. 2008;26(6):463–476.
- Kotsopoulos IA, Evers SM, Ament AJ, et al. Estimating the costs of epilepsy: an international comparison of epilepsy cost studies. Epilepsia. 2001 May;42(5):634–640.
- Beghi E, Atzeni L, Garattini L. Economic analysis of newer antiepileptic drugs. CNS Drugs. 2008;22(10):861–875.
- Allers K, Essue BM, Hackett ML, et al. The economic impact of epilepsy: a systematic review. BMC Neurol. 2015 Nov 25;15:245.
- Begley CE, Annegers JF, Lairson DR, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia. 1994 Nov-Dec;35(6):1230–1243.
- Garattini L, Ricci E, Roggeri D, et al. Costs of epilepsy care in referral centers in Italy. Eur J Health Econ. 2000 Nov;1(2):111–115.
- Bolin K, Lundgren A, Berggren F, et al. Epilepsy in Sweden: health care costs and loss of productivity–a register-based approach. Eur J Health Econ. 2012 Dec;13(6):819–826.
- Jennum P, Gyllenborg J, Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia. 2011 May;52(5):949–956.
- Willems LM, Richter S, Watermann N, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview. Epilepsy Behav. 2018Jun;83:28–35.
- Guekht A, Mizinova M, Kaimovsky I, et al. The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow. Epilepsy Behav. 2016 Nov;64(Pt A):122–126.
- Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia. 2010 May;51(5):838–844. .
- Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics. 2010;28(8):675–685.
- Chmielewska B. Kontrowersje w leczeniu chorych z padaczkami lekoopornymi. Polski Przegląd Neurologiczny. 2008;4(A):44–46.
- Penberthy LT, Towne A, Garnett LK, et al. Estimating the economic burden of status epilepticus to the health care system. Seizure. 2005 Jan;14(1):46–51.
- Kortland LM, Alfter A, Bähr O, et al. Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany. Epilepsia. 2016 Dec;57(12):2056–2066.
- Strzelczyk A, Ansorge S, Hapfelmeier J, et al. Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia. 2017 Sep;58(9):1533–1541.
- Strzelczyk A, Griebel C, Lux W, et al. The burden of severely drug-refractory epilepsy: a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German health insurance data. Front Neurol. 2017 Dec 22;8:712.